Andrew Baum
Stock Analyst at Citigroup
(4.47)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PFE Pfizer | Maintains: Neutral | 25 26 | 23.89 | 8.83% | 7 | Aug 6, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Neutral | 51 47 | 46.2 | 1.73% | 10 | Aug 1, 2025 | |
MRK Merck & Co | Downgrades: Neutral | 115 84 | 82.83 | 1.41% | 10 | May 14, 2025 | |
RPRX Royalty Pharma | Maintains: Buy | 60 40 | 36.36 | 10.01% | 2 | Oct 25, 2024 | |
ABBV AbbVie | Maintains: Strong Buy | 170 215 | 218.37 | -1.54% | 11 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 675 895 | 755.09 | 18.53% | 7 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 10 | 8.03 | 24.53% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 5, 2017 |